Cirugía y Cirujanos

Contents by Year, Volume and Issue

Table of Contents

General Information

Instructions for Authors

Message to Editor

Editorial Board

>Journals >Cirugía y Cirujanos >Year 2007, Issue 4

Rubio-Jurado B, Salazar-Páramo M, Medrano-Muñoz F, González-Ojeda A, Nava A
Thrombophilia, autoimmunity, and perioperative thromboprophylaxis
Cir Cir 2007; 75 (4)

Language: Español
References: 45
Page: 313-321
PDF: 146.45 Kb.

[Full text - PDF]


Thrombosis is observed in several areas of medicine. Equilibrium between pro- and anticoagulant factors is required for maintaining blood flow. Tissue injury from multiple causes may induce coagulum formation mediated by coagulation pathway activation. Tissue factor (F III) + F VIIa interacts with both platelet and endothelial cell receptors. This coagulation model displays four stages: a) initiation, b) amplification, c) propagation and d) stabilization. Development of thrombosis is associated with either primary or hereditary and acquired factors. Primary thrombophilia is determined genetically by a hypercoagulative state shown by loss of natural anticoagulant activity, such as antithrombin III, C, S protein or procoagulant activity gaining resistance to activated C protein: factor V (Leiden), prothrombin and methylenetetrahydrofolate reductase mutations. Acquired thrombophilia mainly relates to an autoimmune condition such as the presence of anticardiolipin antibodies or lupus anticoagulant. Surgical procedures enhance mechanisms that predispose to thrombosis, e.g., acidosis, hypothermia, plasma expanders, extracorporeal circulation, duration of surgical procedure, and tissue manipulation. Adequate classification of the patient’s thrombosis risk and adequate use of primary and secondary prophylactic recommendations in these groups of patients is necessary.

Key words: Thrombophilia, autoimmunity, thrombosis, thromboprophylaxi.


  1. 1. Tomokiyo K, Kamikubo Y, Hanada T, et al. Von Willebrand factor accelerates platelet adhesion and thrombus formation on a collagen surface in platelet-reduced blood under flow conditions. Blood 2005;105:1078-1084.

  2. 2. Bombeli T, Spahn DR. Updates in perioperative coagulation: physiology and management of thromboembolism and haemorrhage. Br J Anaesth 2004;93:275-287.

  3. 3. Carrillo ER, Salmerón NP, Carvajal RR, Contreras DV, Hernández AC. Rompiendo un paradigma: del modelo humoral al modelo celular de la coagulación. Su aplicación clínica en el enfermo grave. Med Crit Terapia Inten 2004;XVIII,No1:17-23.

  4. 4. Martínez Murillo C. Bases de la hemostasia y trombosis. Gac Med Mex 2003;139(S2):20-30.

  5. 5. The Heart Outcomes Prevention Evaluation (HOPE) 2 investigators. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 2006;354:1-11.

  6. 6. Mackman N. Role of tissue factor in hemostasis, thrombosis, and vascular development. Arterioscler Thromb Vasc Biol 2004;24:1015-1022.

  7. 7. Ruggeri ZM. Platelets in atherothrombosis. Nat Med 2002;8:1227-1234.

  8. 8. van Hylckama Vlieg A, van der Linden IK, Bertina RM, Rosendaal FR. High levels of factor IX increase the risk of venous thrombosis. Blood 2000;95:3678-3682.

  9. 9. Kyrle PA, Eichinger S. Deep vein thrombosis. Lancet 2005;365:1163-1174.

  10. 10. Dahlbäck B. Blood coagulation and its regulation by anticoagulant pathways: genetic pathogenesis of bleeding and thrombotic diseases. J Intern Med 2005;257:209-223.

  11. 11. Izaguirre-Ávila R. Centenario de la doctrina de la coagulación sanguínea. Arch Cardiol Mex 2005;S3:118-129.

  12. 12. Kaushansky K. The molecular mechanisms that control thrombopoiesis. J Clin Invest 2005;115:3339-3347.

  13. 13. Yuan Y, Dopheide SM, Ivanidis C, Salem HH, Jackson SP. Calpain regulation of cytoskeletal signaling complexes in von Willebrand factor-stimulated platelets. Distinct roles for glycoprotein Ib-V-IX and glycoprotein IIb-IIIa (integrin aIIbb3) in von Willebrand factor-induced signal transduction. J Biol Chem 1997;272:21847-21854.

  14. 14. Shattil SJ, Newman PJ. Integrins: dynamic scaffolds for adhesion and signaling in platelets. Blood 2004;104:1606-1615.

  15. 15. Leon C, Alex M, Klocke A, et al. Platelet ADP receptors contribute to the initiation of intravascular coagulation. Blood 2004;103:594-600.

  16. 16. Carrillo-Esper R, Villaseñor-Ovies P. Coagulopatía del paciente quirúrgico. El nuevo modelo celular de la coagulación y su aplicación en anestesiología. Anestesiologia 2004;27:219-230.

  17. 17. Day SM, Reeve JL, Pedersen B, et al. Macrovascular thrombosis is driven by tissue factor derived primarily from the blood vessel wall. Blood 2005;105:192-198.

  18. 18. Butenas S, Bouchard BA, Brummel-Ziedins KE, Parhami-Seren B, Mann KG. Tissue factor activity in whole blood. Blood 2005;105:2764-2770.

  19. 19. Orfeo T, Butenas S, Brummel-Ziedins KE, Mann KG. The tissue factor requirement in blood coagulation. J Biol Chem 2005;280:42887-42896.

  20. 20. Furie B, Furie BC. Thrombus formation in vivo. J Clin Invest 2005;

  21. 115:3355-3362.

  22. 21. Hertzberg MS. Genetic testing for thrombophilia mutations. Semin Thromb Hemost 2005;31:33-38.

  23. 22. De Stefano V, Rossi E, Paciaroni K, Leone G. Screening for inherited thrombophilia: indications and therapeutic implications. Haematologica 2002;87:1095-1108.

  24. 23. Williamson D, Brown K, Luddington R, Baglin C, Baglin T. Factor V Cambridge: a new mutation (Arg306-->Thr) associated with resistance to activated protein C. Blood 1998;91:1140-1144.

  25. 24. Gutiérrez-Tous MR. Trombofilia, ¿cuándo, qué pruebas y a quién? Sem Fund Esp Reumatol 2005;6:133-143.

  26. 25. Majluf-Cruz A. La realidad de la prevalencia de la trombosis. Gac Med Mex 2003;139(S2):66-68.

  27. 26. Lim W, Crowther M, Eikelboom JW. Management of antiphospholipid antibody syndrome: a systematic review. JAMA 2006;295:1050-1057.

  28. 27. Scaglione L, Piobbici M, Pagano E, Ballini L, Tamponi G, Ciccone G. Implementing guidelines for venous thromboembolism prophylaxis in a large Italian teaching hospital: lights and shadows. Haematologica 2005;90:678-684.

  29. 28. Rosendaal FR, Koster T, Vandenbrouke JP, Reitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 1995;85:1504-1508.

  30. 29. Carmel R, Green R, Rosenblatt DS, Watkins D. Update on cobalamin, folate, and homocysteine. Hematology Am Soc Hematol Educ Program 2003:62-81.

  31. 30. Terzolo M, Allasino B, Bosio S, et al. Hyperhomocysteinemia in patients with Cushing’s syndrome. J Clin Endocrinol Metab 2004;89:3745-3751.

  32. 31. Loscalzo J. Homocysteine trials¾clear outcomes for complex reasons. N Engl J Med 2006;354:1629-1632.

  33. 32. Tripodi A. Levels of coagulation factors and venous thromboembolism. Haematologica 2003;88:705-711.

  34. 33. Johnson CM, Mureebe L, Silver D. Hypercoagulable states: a review. Vasc Endovasc Surg 2005;39:123-133.

  35. 34. Samama MM, Dahl OE, Mismetti P, et al. An electronic tool for venous thromboembolism prevention in medical and surgical patients. Haematologica 2006;91:64-70.

  36. 35. Crowther MA, Guisberg JS, Julian J, et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med 2003;349:1133-1138.

  37. 36. Ortel TL. The antiphospholipid syndrome: what are we really measuring? How do we measure it? And how do we treat it? J Thromb Thrombolysis 2006;21:79-83.

  38. 37. Tofler GH, Massaro J, Levy D, et al. Relation of the prothrombotic state to increasing age (from the Framingham Offspring Study). Am J Cardiol 2005;96:1280-1283.

  39. 38. Edmonds MJ, Crichton TJ, Runciman WB, Pradhan M. Evidence-based risk factors for postoperative deep vein thrombosis. ANZ J Surg 2004;74:1082-1097.

  40. 39. Consenso mexicano sobre la enfermedad tromboembólica venosa. Cir Ciruj 2000;68(suppl 6):S7-S11.

  41. 40. Urwin SC, Parker MJ, Griffiths R. General versus regional anaesthesia for hip fracture surgery: a meta-analysis of randomized trials. Br J Anaesth 2000;84:450-455.

  42. 41. White RH, Gettner S, Newman JM, Trauner KB, Romano PS. Predictors of rehospitalization for symptomatic venous thromboembolism after total hip arthroplasty. N Engl J Med 2000;343:1758-1764.

  43. 42. Salvati EA, Della Valle AG, Westrich GH, et al. The John Charnley Award: heritable thrombophilia and development of thromboembolic disease after total hip arthroplasty. Clin Orthop Relat Res 2005;441:40-55.

  44. 43. Pérez-García A, Briones-Pérez B. Tromboprofilaxis en pacientes posquirúrgicos: revisión de 1,500 casos. Cir Ciruj 2004;72:287-291.

  45. 44. Delgado-Lamas JL. El paciente quirúrgico con riesgo de hemorragia. En: Tratado de cirugía general. Consejo Mexicano de Cirugía General. México: El Manual Moderno;2003. pp. 109-112.

  46. 45. González Della Valle A, Serota A, Go G, et al. Venous thromboembolism is rare with a multimodal prophylaxis protocol after total hip arthroplasty. Clin Orthop Relat Res 2006;444:146-153.

>Journals >Cirugía y Cirujanos >Year 2007, Issue 4

· Journal Index 
· Links 
Copyright 2010